Stevanato Group S.p.a. cash flow statement
In fiscal 2025, Stevanato Group S.p.a.'s operations generated $323m of cash; it spent $298m on capital projects, leaving free cash flow of $25.2m. It returned $16.7m in dividends.
Cash flow statement
| Fiscal year | 2019Dec 2019 | 2020Dec 2020 | 2021Dec 2021 | 2022Dec 2022 | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 |
|---|---|---|---|---|---|---|---|
| Cash from operations | 48 | 178 | 158 | 109 | 114 | 169 | 323 |
| Depreciation and amortisation | 52 | 62 | 67 | 68 | 85 | — | — |
| Capital spending | 76 | 102 | 127 | 248 | 469 | 327 | 298 |
| Free cash flow | −29 | 75 | 30 | −139 | −355 | −159 | 25 |
| Dividends paid | 7 | 10 | 13 | 14 | 15 | 16 | 17 |
Compare with peers
- Haemonetics Corp cash flow
- Penumbra Inc cash flow
- Merit Medical Systems Inc cash flow
- Integra Lifesciences Holdings Corp cash flow
- Tandem Diabetes Care Inc cash flow
Head to head: HAE vs STVNPEN vs STVNMMSI vs STVN
More: Health Care Equipment stocks compared, Health Care sector, rankings of US companies